Global Operation Targets AI-Generated Child Abuse Material, Leading to Over 25 Arrests

Novo Nordisk, Europe’s largest pharmaceutical company, has reported a remarkable 86% increase in sales of its weight-loss drug Wegovy, bolstered by a favorable revenue report of 290 billion Danish kroner ($43.4 billion) for the previous year. Despite concerns regarding potential tariffs on imports from the U.S., CEO Lars Fruergaard Jørgensen expressed confidence in the company’s ability to navigate the changing trade landscape.
The tariffs, threatened by U.S. President Donald Trump, specifically target countries such as Canada, Mexico, and China, but Jørgensen reassured stakeholders that Novo Nordisk is positioned to adapt. Alongside the growth of Wegovy, sales of its diabetes treatment Ozempic also rose by 26%.
Innovations in drug development are on the horizon as Novo plans to seek regulatory approval for its new obesity treatment, CagriSema, after mixed results in clinical trials. The company aims to cater to an expanding market for obesity treatments, with over 45 million patients currently benefiting from its therapies.